[Corrigendum] Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer.

The article focuses on a correction to a previously published study investigating the role of Rac1 (Ras-related C3 botulinum toxin substrate 1) knockdown in reducing migration and invasion of enzalutamide-resistant prostate cancer (PCa) cells. An error was identified in Figure 3A, where two data panels appeared to overlap, indicating incorrect assembly of the figure. The authors reviewed their original data, corrected the figure, and stated that this mistake did not significantly affect the study’s results or conclusions. The correction includes updated Transwell migration and invasion assay data demonstrating the effects of Rac1 depletion combined with enzalutamide treatment on PCa cells. [Extracted from the article]

Copyright of Oncology Letters is the property of Spandidos Publications UK Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)